MediWound

Develops enzymatic biological therapies for burn eschar removal and wound tissue repair.

HealthtechEstablished

About

NexoBrid® EscharEx® About MediWound One Pager Corporate Deck Recent Updates A New Paradigm in Treatment of Severe Burns Indication: Eschar removal in deep partial-thickness and full-thickness thermal burns Classification: Orphan biological drug Target Audience: Hospitalized patients Status: U.S./EU/

Key facts

Domain: mediwound.com
Sector: Healthtech
Language: en-US
Last checked: 2026-10-29

Links

Websitemediwound.com Careersmediwound.com/careers

Sources

Company site: https://mediwound.com/ (fetched 2026-10-29)

Data for this page: JSON · last checked 2026-10-29

Is this your company?

Claim the page with an email at your company domain, then fix facts and add what is missing. Free.

Claim this page